AbbVie Biotechnology Ltd., IPR2018-00156, Paper 11 (June 5, 2018) (informative as to section III.C.1) (here) This decision determines that the Petitioner made a sufficient showing for purposes of institution that a drug package insert was publicly available, where the record included a screenshot of an archived FDA webpage from the Internet Archive and testimony from a medical doctor describing the use and accessibility of information on the FDA’s webpage. [read post]

 Fujifilm v AbbVie: practice, procedure and policy analysisGuest Kat Eibhlin Vardy summarizes the Rapid Response event organized by AIPPI on the case Fujifilm Kyowa Kirin Biologics Company Limited v AbbVie Biotechnology Limited, [2017] EWHC 395 (Pat), from the perspective of patent and competition law.Overturning a trade mark opposition decision - Part 2 - SOULUXE - likelihood of confusionGuest Kat Rosie Burbidge recaps the case SoulCycle Inc v Matalan Ltd,… [read post]

| Actavis v Lilly | EU public consultation on neighbouring rights | Life as an IP Lawyer in San Francisco | Copyright in chess games | Trade surplus and IP | Fujifilm Kyowa Biologics v AbbVie Biotechnology. [read post]

., Ltd and Others v AbbVie Biotechnology Limited by summarising the latest timeline events.BREAKING: High Court grants declaration that products obvious/anticipated at claimed priority datesFollowing AmeriKat’s notice, Eibhlin Vardy timely analysed the High Court’s decision on 3 March that granted declarations to Fujifilm Kyowa Kirin Biologics and Samsung Bioepsis and Biogen Idec to the effect that their products lacked novelty or an inventive step at a… [read post]